Difference between revisions of "Acute promyelocytic leukemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - ", et al. " to " et al. ")
Line 33: Line 33:
  
 
==APML4 induction ==
 
==APML4 induction ==
−
===Regimen, Iland, et al. 2012 (APML4)===
+
===Regimen, Iland et al. 2012 (APML4)===
 
Level of Evidence:
 
Level of Evidence:
 
<span
 
<span
Line 84: Line 84:
 
AIDA: '''<u>A</u>'''TRA, '''<u>IDA</u>'''rubicin
 
AIDA: '''<u>A</u>'''TRA, '''<u>IDA</u>'''rubicin
  
−
===Regimen, Avvisati, et al. 1996; Lo-Coco, et al. 2010 (AIDA 2000); Latagliata, et al. 2011 (AIDA 0493); Avvisati, et al. 2011 (AIDA 0493); Lo-Coco, et al. 2013===
+
===Regimen, Avvisati et al. 1996; Lo-Coco et al. 2010 (AIDA 2000); Latagliata et al. 2011 (AIDA 0493); Avvisati et al. 2011 (AIDA 0493); Lo-Coco et al. 2013===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 154: Line 154:
  
 
==ATRA & Arsenic==
 
==ATRA & Arsenic==
−
===Regimen #1, Lo-Coco, et al. 2013===
+
===Regimen #1, Lo-Coco et al. 2013===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 163: Line 163:
 
border-style:solid;">Phase III</span>
 
border-style:solid;">Phase III</span>
  
−
''Lo-Coco, et al. 2013 excluded patients with high-risk APML (white blood cell count at presentation ≥10 x 10<sup>9</sup>/L)''
+
''Lo-Coco et al. 2013 excluded patients with high-risk APML (white blood cell count at presentation ≥10 x 10<sup>9</sup>/L)''
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.
 
*[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV over 2 hours once per day, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.
 
*[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV over 2 hours once per day, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.
Line 176: Line 176:
 
To be followed by [[#ATRA_.26_Arsenic_-_consolidation|ATRA & Arsenic consolidation therapy]].
 
To be followed by [[#ATRA_.26_Arsenic_-_consolidation|ATRA & Arsenic consolidation therapy]].
  
−
===Regimen #2, Estey, et al. 2006 & Ravandi, et al. 2009===
+
===Regimen #2, Estey et al. 2006 & Ravandi et al. 2009===
 
Level of Evidence:
 
Level of Evidence:
 
<span
 
<span
Line 185: Line 185:
 
border-style:solid;">Phase II</span>
 
border-style:solid;">Phase II</span>
  
−
''The original protocol was modified between Estey, et al. 2006 and Ravandi, et al. 2009.  Estey, et al. 2006 covered part of the whole cohort.  In the initial protocol, arsenic trioxide was started on day 11, and gemtuzumab ozogamicin was only used for high risk patients.  After a death due to hyperleukocytosis and intracranial hemorrhage during induction, the protocol was modified as described in Ravandi, et al. 2009 so arsenic trioxide was started on day 1, and gemtuzumab ozogamicin was given if WBC count went >30 x 10<sup>9</sup>/L for any patient in the first four weeks of therapy.''
+
''The original protocol was modified between Estey et al. 2006 and Ravandi et al. 2009.  Estey et al. 2006 covered part of the whole cohort.  In the initial protocol, arsenic trioxide was started on day 11, and gemtuzumab ozogamicin was only used for high risk patients.  After a death due to hyperleukocytosis and intracranial hemorrhage during induction, the protocol was modified as described in Ravandi et al. 2009 so arsenic trioxide was started on day 1, and gemtuzumab ozogamicin was given if WBC count went >30 x 10<sup>9</sup>/L for any patient in the first four weeks of therapy.''
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until remission or maximum of 90 days.
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until remission or maximum of 90 days.
−
*[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV over 1 hour once per day, starting on day 11 and continuing until remission (as described in Estey, et al. 2006)
+
*[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV over 1 hour once per day, starting on day 11 and continuing until remission (as described in Estey et al. 2006)
−
**Patients in Ravandi, et al. 2009 received [[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV over 1 hour once per day, starting on day 1 and continuing until remission
+
**Patients in Ravandi et al. 2009 received [[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV over 1 hour once per day, starting on day 1 and continuing until remission
 
*Patients with high-risk disease (initial WBC ≥10 x 10<sup>9</sup>/L) received: [[Gemtuzumab ozogamicin (Mylotarg)]] 9 mg/m2 IV once on day 1
 
*Patients with high-risk disease (initial WBC ≥10 x 10<sup>9</sup>/L) received: [[Gemtuzumab ozogamicin (Mylotarg)]] 9 mg/m2 IV once on day 1
 
**Patients who initially were not high-risk but subsequently developed WBC ≥10 x 10<sup>9</sup>/L during the first four weeks of therapy received: [[Gemtuzumab ozogamicin (Mylotarg)]] 9 mg/m2 IV once
 
**Patients who initially were not high-risk but subsequently developed WBC ≥10 x 10<sup>9</sup>/L during the first four weeks of therapy received: [[Gemtuzumab ozogamicin (Mylotarg)]] 9 mg/m2 IV once
Line 195: Line 195:
 
*"Prophylactic and therapeutic antibiotics and transfusion of blood products to maintain platelet counts more than 30 x 10<sup>9</sup>/L, fibrinogen more than 150 mg/dL, and the international normalized ratio for prothrombin time less than 1.5" per institutional guidelines
 
*"Prophylactic and therapeutic antibiotics and transfusion of blood products to maintain platelet counts more than 30 x 10<sup>9</sup>/L, fibrinogen more than 150 mg/dL, and the international normalized ratio for prothrombin time less than 1.5" per institutional guidelines
 
*[[Heparin]] or [[Tranexamic acid (Cyklokapron)]] used if clinically indicated
 
*[[Heparin]] or [[Tranexamic acid (Cyklokapron)]] used if clinically indicated
−
*Patients in Estey, et al. 2006 received: "Oral solumedrol" 20 mg PO once per day x 10 days to decrease risk of differentiation syndrome  
+
*Patients in Estey et al. 2006 received: "Oral solumedrol" 20 mg PO once per day x 10 days to decrease risk of differentiation syndrome  
−
*Patients in Ravandi, et al. 2009 recieved: [[Methylprednisolone (Solumedrol)|Methylprednisolone]] 50 mg PO once per day x 5 days to decrease risk of differentiation syndrome  
+
*Patients in Ravandi et al. 2009 recieved: [[Methylprednisolone (Solumedrol)|Methylprednisolone]] 50 mg PO once per day x 5 days to decrease risk of differentiation syndrome  
  
 
To be followed by [[#ATRA_.26_Arsenic_-_consolidation|ATRA & Arsenic consolidation therapy]].
 
To be followed by [[#ATRA_.26_Arsenic_-_consolidation|ATRA & Arsenic consolidation therapy]].
  
−
===Regimen #3, Shen, et al. 2004===
+
===Regimen #3, Shen et al. 2004===
 
Level of Evidence:
 
Level of Evidence:
 
<span
 
<span
Line 244: Line 244:
 
*[[Cytarabine (Cytosar)]] 1000 mg/m2 IV every 12 hours on days 1 to 4 (8 total doses)
 
*[[Cytarabine (Cytosar)]] 1000 mg/m2 IV every 12 hours on days 1 to 4 (8 total doses)
  
−
'''Note: Adès, et al. 2006 and Adès, et al. 2008 both do not say that IT chemotherapy is used for patients with age >60 and WBC >10 x 10^9/L, but figure 1 in Adès, et al. 2006 depicts IT chemotherapy in this patient group.  I did not see a reference that clearly resolved this contradiction.'''
+
'''Note: Adès et al. 2006 and Adès et al. 2008 both do not say that IT chemotherapy is used for patients with age >60 and WBC >10 x 10^9/L, but figure 1 in Adès et al. 2006 depicts IT chemotherapy in this patient group.  I did not see a reference that clearly resolved this contradiction.'''
  
 
===Consolidation regimen for patients ≤60 years old and WBC >10 x 10^9/L===
 
===Consolidation regimen for patients ≤60 years old and WBC >10 x 10^9/L===
Line 272: Line 272:
 
Preceded by [[#APML4_induction|APML4 induction]] therapy.
 
Preceded by [[#APML4_induction|APML4 induction]] therapy.
  
−
===Regimen, Iland, et al. 2012 (APML4)===
+
===Regimen, Iland et al. 2012 (APML4)===
 
Level of Evidence:
 
Level of Evidence:
 
<span
 
<span
Line 364: Line 364:
 
Preceded by [[#AIDA_0493_.26_AIDA_2000_induction|AIDA 0493 & AIDA 2000 induction]] therapy.
 
Preceded by [[#AIDA_0493_.26_AIDA_2000_induction|AIDA 0493 & AIDA 2000 induction]] therapy.
  
−
===Regimen, Lo-Coco, et al. 2010 (AIDA 2000)===
+
===Regimen, Lo-Coco et al. 2010 (AIDA 2000)===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 374: Line 374:
  
 
====Low or intermediate risk====
 
====Low or intermediate risk====
−
''Patients with initial WBC <10 x 10<sup>9</sup>/L were considered to be low or intermediate risk.  Lo-Coco, et al. 2010 was unclear about how many days--if any--were between each part of consolidation therapy.''
+
''Patients with initial WBC <10 x 10<sup>9</sup>/L were considered to be low or intermediate risk.  Lo-Coco et al. 2010 was unclear about how many days--if any--were between each part of consolidation therapy.''
 
*[[Idarubicin (Idamycin)]] 5 mg/m2 IV once per day on days 1 to 4
 
*[[Idarubicin (Idamycin)]] 5 mg/m2 IV once per day on days 1 to 4
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day PO for a total of 15 days
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day PO for a total of 15 days
Line 541: Line 541:
 
Preceded by [[#ATRA_.26_Arsenic|ATRA & Arsenic]] induction therapy.
 
Preceded by [[#ATRA_.26_Arsenic|ATRA & Arsenic]] induction therapy.
  
−
===Regimen, Estey, et al. 2006 & Lo-Coco, et al. 2013===
+
===Regimen, Estey et al. 2006 & Lo-Coco et al. 2013===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 586: Line 586:
 
Preceded by [[#APML4_consolidation|APML4 consolidation]] therapy.
 
Preceded by [[#APML4_consolidation|APML4 consolidation]] therapy.
  
−
===Regimen, Iland, et al. 2012 (APML4)===
+
===Regimen, Iland et al. 2012 (APML4)===
 
Level of Evidence:
 
Level of Evidence:
 
<span
 
<span
Line 632: Line 632:
 
border-style:solid;">Phase III</span>
 
border-style:solid;">Phase III</span>
  
−
''See Avvisati, et al. 2011 for details about outcomes with or without maintenance therapy.  Treatment options investigated included only using Part A, only using Part B, or alternating between the two, in all cases for a total of 2 years.''
+
''See Avvisati et al. 2011 for details about outcomes with or without maintenance therapy.  Treatment options investigated included only using Part A, only using Part B, or alternating between the two, in all cases for a total of 2 years.''
  
 
====Part A====
 
====Part A====
Line 645: Line 645:
 
'''90-day course of therapy, alternating with part A, given for a total of 2 years'''
 
'''90-day course of therapy, alternating with part A, given for a total of 2 years'''
  
−
===Alternate regimen (Avvisati, et al. 2002)===
+
===Alternate regimen (Avvisati et al. 2002)===
 
*[[Mercaptopurine (Purinethol)]] 1 mg/kg PO daily  
 
*[[Mercaptopurine (Purinethol)]] 1 mg/kg PO daily  
 
*[[Methotrexate (MTX)]] 0.25 mg/kg IM weekly  
 
*[[Methotrexate (MTX)]] 0.25 mg/kg IM weekly  
Line 659: Line 659:
 
Preceded by [[#AIDA_2000_consolidation|AIDA 2000 consolidation]] therapy.
 
Preceded by [[#AIDA_2000_consolidation|AIDA 2000 consolidation]] therapy.
  
−
===Regimen, Lo-Coco, et al. 2010 (AIDA 2000)===
+
===Regimen, Lo-Coco et al. 2010 (AIDA 2000)===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 677: Line 677:
  
 
====Part B====
 
====Part B====
−
''Lo-Coco, et al. 2010 did not list details about ATRA; this is how it was given in Avvisati, et al. 2011 (AIDA 0493).''
+
''Lo-Coco et al. 2010 did not list details about ATRA; this is how it was given in Avvisati et al. 2011 (AIDA 0493).''
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 15
 
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID on days 1 to 15
  
Line 703: Line 703:
 
==Arsenic-based re-induction followed by consolidation and autologous stem cell transplant==
 
==Arsenic-based re-induction followed by consolidation and autologous stem cell transplant==
  
−
===Regimen, Yanada, et al. 2013===
+
===Regimen, Yanada et al. 2013===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  

Revision as of 23:08, 17 October 2013

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


Induction therapy

APL 2000 (EAPLG) induction

Regimen

Level of Evidence: Phase III

9-day course of initial induction chemotherapy, with ongoing use of ATRA

If >60 years old and WBC <10 x 10^9/L:

To be followed by APL 2000 (EAPLG) consolidation therapy.

References

  1. Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
  2. Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed

APML4 induction

Regimen, Iland et al. 2012 (APML4)

Level of Evidence: Phase II

36-day course; after 3 to 4 weeks, proceed to consolidation cycle 1

Supportive medications:

  • Prednisone (Sterapred) 1 mg/kg PO once per day on days 1 to 10, or until WBC falls below 1 x 109/L (1,000/uL), or until resolution of differentiation syndrome (whichever occurs last)
  • Hemostatic support : Values checked and products transfused once or twice per day to keep platelet count > 30 x 109/L (30,000/uL), fibrinogen >1.5 g/L (150 mg/dL), normal PT and PTT
  • Electrolyte support while on Arsenic trioxide (Trisenox): supplemental potassium and magnesium given to keep levels in the upper half of their normal ranges

To be followed by APML4 consolidation therapy

References

  1. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R,Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80. Epub 2012 Jun 19. link to original article contains verified protocol PubMed

North American Leukemia Intergroup Study C9710 induction

Regimen

Level of Evidence: Phase III

9-day initial induction chemotherapy, with ongoing use of ATRA

To be followed by North American Leukemia Intergroup Study C9710 consolidation therapy.

References

  1. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol PubMed

AIDA 0493 & AIDA 2000 induction

AIDA: ATRA, IDArubicin

Regimen, Avvisati et al. 1996; Lo-Coco et al. 2010 (AIDA 2000); Latagliata et al. 2011 (AIDA 0493); Avvisati et al. 2011 (AIDA 0493); Lo-Coco et al. 2013

Level of Evidence: Phase III

  • All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission or maximum of 90 days.

8-day initial induction chemotherapy, with ongoing use of ATRA

To be followed by AIDA 0493 consolidation or AIDA 2000 consolidation therapy.

References

  1. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996 Aug 15;88(4):1390-8. link to full article contains verified protocol PubMed
  2. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 8;116(17):3171-9. Epub 2010 Jul 19. link to original article contains verified protocol PubMed
  3. Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. doi: 10.1111/j.1365-2141.2011.08593.x. Epub 2011 Jul 14. link to full article contains verified protocol PubMed
  4. Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
  5. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. link to original article contains verified protocol PubMed

PETHEMA LPA99, LPA2005 induction

PETHEMA: Programa Español de Tratamientos en HEMAtología

Regimen

8-day initial induction chemotherapy, with ongoing use of ATRA

To be followed by PETHEMA LPA99 or PETHEMA LPA2005 consolidation therapy.

References

  1. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
  2. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article contains verified protocol PubMed

Arsenic monotherapy

Regimen

Level of Evidence: Phase III

given until complete remission (CR) or maximum of 75 days (maximum of 60 days after 2001)

If in CR, wait 4 weeks, then:

28-day course

If in CR, wait 4 weeks, then:

1-month cycles x 6 months

References

  1. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24. link to original article contains verified protocol PubMed
  2. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1;107(7):2627-32. Epub 2005 Dec 13. link to original article contains verified protocol PubMed
  3. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P,Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010 Aug 20;28(24):3866-71. doi: 10.1200/JCO.2010.28.5031. Epub 2010 Jul 19. link to original article PubMed

ATRA & Arsenic

Regimen #1, Lo-Coco et al. 2013

Level of Evidence: Phase III

Lo-Coco et al. 2013 excluded patients with high-risk APML (white blood cell count at presentation ≥10 x 109/L)

  • All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.
  • Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 2 hours once per day, starting on day 1 and continuing until hematologic complete remission or maximum of 60 days.

Supportive medications:

  • Prednisone (Sterapred) 0.5 mg/kg PO once per day from days 1 until the end of induction or the onset of differentiation syndrome
    • Patients who develop differentiation syndrome then received: Dexamethasone (Decadron) 10 mg IV every 12 hours until signs and symptoms resolve, and for a minimum of 3 days
  • Hemostatic support: Transfusions to keep platelet count >30 x 109/L (30,000/uL) for the first 10 days of induction and >20 x 109/L (20,000/uL) for the remainder of induction
  • Patients with WBC >10 x 109/L (10,000/uL) and < 50 x 109/L (50,000/uL) after the start of therapy received: Hydroxyurea (Hydrea) 500 mg PO four times per day, given until WBC is <10 x 109/L (10,000/uL)
    • Patients with WBC >50 x 109/L (50,000/uL) after the start of therapy received: Hydroxyurea (Hydrea) 1000 mg PO four times per day, given until WBC is <10 x 109/L (10,000/uL)

To be followed by ATRA & Arsenic consolidation therapy.

Regimen #2, Estey et al. 2006 & Ravandi et al. 2009

Level of Evidence: Phase II

The original protocol was modified between Estey et al. 2006 and Ravandi et al. 2009. Estey et al. 2006 covered part of the whole cohort. In the initial protocol, arsenic trioxide was started on day 11, and gemtuzumab ozogamicin was only used for high risk patients. After a death due to hyperleukocytosis and intracranial hemorrhage during induction, the protocol was modified as described in Ravandi et al. 2009 so arsenic trioxide was started on day 1, and gemtuzumab ozogamicin was given if WBC count went >30 x 109/L for any patient in the first four weeks of therapy.

  • All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting on day 1 and continuing until remission or maximum of 90 days.
  • Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 1 hour once per day, starting on day 11 and continuing until remission (as described in Estey et al. 2006)
    • Patients in Ravandi et al. 2009 received Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 1 hour once per day, starting on day 1 and continuing until remission
  • Patients with high-risk disease (initial WBC ≥10 x 109/L) received: Gemtuzumab ozogamicin (Mylotarg) 9 mg/m2 IV once on day 1
    • Patients who initially were not high-risk but subsequently developed WBC ≥10 x 109/L during the first four weeks of therapy received: Gemtuzumab ozogamicin (Mylotarg) 9 mg/m2 IV once

Supportive medications:

  • "Prophylactic and therapeutic antibiotics and transfusion of blood products to maintain platelet counts more than 30 x 109/L, fibrinogen more than 150 mg/dL, and the international normalized ratio for prothrombin time less than 1.5" per institutional guidelines
  • Heparin or Tranexamic acid (Cyklokapron) used if clinically indicated
  • Patients in Estey et al. 2006 received: "Oral solumedrol" 20 mg PO once per day x 10 days to decrease risk of differentiation syndrome
  • Patients in Ravandi et al. 2009 recieved: Methylprednisolone 50 mg PO once per day x 5 days to decrease risk of differentiation syndrome

To be followed by ATRA & Arsenic consolidation therapy.

Regimen #3, Shen et al. 2004

Level of Evidence: Phase II

All patients achieving CR went on to receive chemotherapy-based consolidation and maintenance. These details are available in the original paper but are omitted here.

References

  1. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24. link to original article contains verified protocol PubMed
  2. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006 May 1;107(9):3469-73. Epub 2005 Dec 22. link to original article contains verified protocol PubMed
  3. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 1;27(4):504-10. doi: 10.1200/JCO.2008.18.6130. Epub 2008 Dec 15. link to original article contains verified protocol PubMed
  4. Update: Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7. Epub 2009 Feb 18. link to original article contains verified protocol PubMed
  5. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. link to original article link to supplementary appendix link to protocol contains verified protocol PubMed

Consolidation therapy

APL 2000 (EAPLG) consolidation

Preceded by APL 2000 (EAPLG) induction therapy.

Regimen

Level of Evidence: Phase III

Consolidation regimen for patients ≤60 years old and WBC <10 x 10^9/L or age >60 and WBC >10 x 10^9/L

Followed by:

Note: Adès et al. 2006 and Adès et al. 2008 both do not say that IT chemotherapy is used for patients with age >60 and WBC >10 x 10^9/L, but figure 1 in Adès et al. 2006 depicts IT chemotherapy in this patient group. I did not see a reference that clearly resolved this contradiction.

Consolidation regimen for patients ≤60 years old and WBC >10 x 10^9/L

Followed by:

Consolidation regimen for patients >60 years old and WBC <10 x 10^9/L

Followed by:

To be followed by APL 2000 (EAPLG) maintenance therapy.

References

  1. Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
  2. Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed

APML4 consolidation

Preceded by APML4 induction therapy.

Regimen, Iland et al. 2012 (APML4)

Level of Evidence: Phase II

Consolidation cycle 1

Given 3 to 4 weeks after completion of induction.

4-week course; after 3 to 4 weeks, proceed to consolidation cycle 2

Consolidation cycle 2

Given 3 to 4 weeks after completion of consolidation cycle 1.

5-week course; after 3 to 4 weeks, proceed to APML4 maintenance

References

  1. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R,Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80. Epub 2012 Jun 19. link to original article contains verified protocol PubMed

North American Leukemia Intergroup Study C9710 consolidation

Preceded by North American Leukemia Intergroup Study C9710 induction therapy.

Regimen

Level of Evidence: Phase III

Consolidation therapy starts within 2 to 4 weeks of hematologic remission:

7-week cycles (5 weeks of therapy, then 2 weeks off), THEN

7-day cycles x 2 cycles

To be followed by North American Leukemia Intergroup Study C9710 maintenance therapy.

References

  1. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol PubMed

AIDA 0493 consolidation

AIDA: ATRA, IDArubicin
Preceded by AIDA 0493 induction therapy.

Regimen

Level of Evidence: Phase III

As detailed in Avvisati, et al., 2002:

  • Idarubicin (Idamycin) 5 mg/m2 IV once daily on days 1 to 4 (administered second, 3 hours after cytarabine infusion complete)
  • Cytarabine (Cytosar) 1000 mg/m2 IV over 6 hours on days 1 to 4 (administered first)

4-day course of therapy, THEN

5-day course of therapy, THEN

5-day course of therapy

To be followed by AIDA 0493 maintenance therapy.

References

  1. Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains verified protocol PubMed
  2. Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. doi: 10.1111/j.1365-2141.2011.08593.x. Epub 2011 Jul 14. link to full article contains verified protocol PubMed
  3. Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed

AIDA 2000 consolidation

AIDA: ATRA, IDArubicin
Preceded by AIDA 0493 & AIDA 2000 induction therapy.

Regimen, Lo-Coco et al. 2010 (AIDA 2000)

Level of Evidence: Phase II

Low or intermediate risk

Patients with initial WBC <10 x 109/L were considered to be low or intermediate risk. Lo-Coco et al. 2010 was unclear about how many days--if any--were between each part of consolidation therapy.

4-day course of therapy, THEN

5-day course of therapy, THEN

To be followed by AIDA 2000 maintenance therapy.

High risk

Patients with initial WBC >10 x 109/L were considered to be high risk.

"Before the initiation of each consolidation cycle," high-risk patients received intracranial prophylaxis:

"total of 3 courses"

4-day course of therapy, THEN

5-day course of therapy, THEN

5-day course of therapy

To be followed by AIDA 2000 maintenance therapy.

References

  1. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 8;116(17):3171-9. Epub 2010 Jul 19. link to original article contains verified protocol PubMed

PETHEMA LPA99 consolidation

PETHEMA: Programa Español de Tratamientos en HEMAtología
Preceded by PETHEMA LPA99, LPA2005 induction therapy.

Regimen

High risk:

1-month cycle, THEN

1-month cycle, THEN

1-month cycle

Intermediate risk:

1-month cycle, THEN

1-month cycle, THEN

1-month cycle

Low risk:

1-month cycle, THEN

1-month cycle, THEN

1-month cycle

To be followed by PETHEMA LPA99, LPA2005 maintenance therapy.

References

  1. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
  2. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article contains verified protocol PubMed

PETHEMA LPA2005 consolidation

PETHEMA: Programa Español de Tratamientos en HEMAtología
Preceded by PETHEMA LPA99, LPA2005 induction therapy.

Regimen

High risk:

1-month cycle, THEN

1-month cycle, THEN

1-month cycle

Intermediate risk:

1-month cycle, THEN

1-month cycle, THEN

1-month cycle

Low risk:

1-month cycle, THEN

1-month cycle, THEN

1-month cycle

To be followed by PETHEMA LPA99, LPA2005 maintenance therapy.

References

  1. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
  2. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article contains verified protocol PubMed

ATRA & Arsenic - consolidation

Preceded by ATRA & Arsenic induction therapy.

Regimen, Estey et al. 2006 & Lo-Coco et al. 2013

Level of Evidence: Phase II

  • All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, 7 days per week on weeks 1 to 2, 5 to 6, 9 to 10, 13 to 14, 17 to 18, 21 to 22, 25 to 26
  • Arsenic trioxide (Trisenox) 0.15 mg/kg IV over 1 to 2 hours once per day, 5 consecutive days per week, on weeks 1 to 4, 9 to 12, 17 to 20, 25 to 28

28 weeks of therapy

References

  1. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006 May 1;107(9):3469-73. Epub 2005 Dec 22. link to original article contains verified protocol PubMed
  2. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. link to original article link to supplementary appendix link to protocol contains verified protocol PubMed

Maintenance therapy

APL 2000 (EAPLG) maintenance

Preceded by APL 2000 (EAPLG) consolidation therapy.

Regimen

Level of Evidence: Phase III

90-day cycles x 2 years

References

  1. Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20. link to original article contains verified protocol PubMed
  2. Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1. link to original article contains verified protocol PubMed


APML4 maintenance

Preceded by APML4 consolidation therapy.

Regimen, Iland et al. 2012 (APML4)

Level of Evidence: Phase II

Given 3 to 4 weeks after completion of consolidation cycle 2.

90-day cycles x 8 cycles

References

  1. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R,Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80. Epub 2012 Jun 19. link to original article contains verified protocol PubMed

North American Leukemia Intergroup Study C9710 maintenance

Preceded by North American Leukemia Intergroup Study C9710 consolidation therapy.

Regimen

Maintenance therapy starts 2 to 4 weeks after recovery from consolidation therapy:

With or without:

1 year of therapy

References

  1. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. Epub 2010 Aug 12. link to original article contains verified protocol PubMed

AIDA 0493 maintenance

Preceded by AIDA 0493 consolidation therapy.

Regimen

Level of Evidence: Phase III

See Avvisati et al. 2011 for details about outcomes with or without maintenance therapy. Treatment options investigated included only using Part A, only using Part B, or alternating between the two, in all cases for a total of 2 years.

Part A

90-day course of therapy, alternating with part B, given for a total of 2 years

Part B

90-day course of therapy, alternating with part A, given for a total of 2 years

Alternate regimen (Avvisati et al. 2002)

2-year course of therapy

References

  1. Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains verified protocol PubMed
  2. Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains verified protocol PubMed
  3. Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. doi: 10.1111/j.1365-2141.2011.08593.x. Epub 2011 Jul 14. link to original article contains verified protocol PubMed

AIDA 2000 maintenance

Preceded by AIDA 2000 consolidation therapy.

Regimen, Lo-Coco et al. 2010 (AIDA 2000)

Level of Evidence: Phase II

Patients RT-PCR negative for PML/RARA after consolidation received maintenance therapy. Patients who were RT-PCR positive for PML/RARA after consolidation were considered to have resistant disease and were given salvage therapy.

Part A

90-day course of therapy, alternating with part B, given for a total of 2 years

Part B

Lo-Coco et al. 2010 did not list details about ATRA; this is how it was given in Avvisati et al. 2011 (AIDA 0493).

90-day course of therapy, alternating with part A, given for a total of 2 years

References

  1. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 8;116(17):3171-9. Epub 2010 Jul 19. link to original article contains verified protocol PubMed

PETHEMA LPA99, LPA2005 maintenance

PETHEMA: Programa Español de Tratamientos en HEMAtología
Preceded by PETHEMA LPA99 or PETHEMA LPA2005 consolidation therapy.

Regimen

90-day cycles x 2 years

References

  1. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23. link to original article contains verified protocol PubMed
  2. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. Epub 2010 Apr 14. link to original article PubMed

Relapsed/refractory

Arsenic-based re-induction followed by consolidation and autologous stem cell transplant

Regimen, Yanada et al. 2013

Level of Evidence: Phase II

Induction

Consolidation #1 and #2

Consolidation #3

Peripheral blood stem cells collected upon WBC recovery, followed by:

References

  1. Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. doi: 10.1182/blood-2012-11-466862. Epub 2013 Feb 14. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Acute_promyelocytic_leukemia&oldid=3845"